GSK Acquires RAPT Therapeutics for $2.2 Billion

• The acquisition is valued at $2.2 billion in total transaction value
• RAPT Therapeutics is a U.S.-based biotechnology company being purchased by British pharma giant GSK
• The deal adds to GSK's strategy of expanding through targeted acquisitions in the biotech sector

GSK Acquires RAPT Therapeutics for $2.2 Billion

British pharmaceutical giant GSK (GlaxoSmithKline) announced on January 20 the acquisition of U.S.-based RAPT Therapeutics for $2.2 billion, marking a significant strategic expansion in its biopharmaceutical portfolio.

Key Transaction Details

Acquirer: GSK (GlaxoSmithKline)

Target: RAPT Therapeutics (U.S.-based)

Deal Value: $2.2 billion

Announcement Date: January 20, 2026

Companies and Sector

This transaction involves GSK, one of the world's leading pharmaceutical companies, acquiring RAPT Therapeutics, a U.S. biotechnology firm. The deal falls within the healthcare and pharmaceuticals sector, specifically the biotechnology space.

Market Implications

This acquisition represents GSK's continued strategic investment in expanding its therapeutic capabilities and pipeline. The $2.2 billion price tag signals GSK's confidence in RAPT's technology platform and potential products. For the broader pharmaceutical sector, this deal reflects ongoing consolidation trends as major pharmaceutical companies seek to bolster their pipelines through acquisitions of specialized biotech firms.

The transaction also highlights the value premium placed on innovative biotechnology companies with promising therapeutic platforms, as larger pharmaceutical firms compete to secure next-generation treatments and maintain competitive positioning in rapidly evolving therapeutic areas.

For investors, this acquisition may impact GSK's near-term capital allocation but could strengthen its long-term growth prospects depending on RAPT's pipeline assets and their clinical development potential.

Note: The original article provided limited details beyond the basic transaction announcement. Additional information about RAPT's specific therapeutic focus, pipeline assets, and deal structure was not disclosed in the source material.